{
  "id": "58962dac78275d0c4a000005",
  "type": "summary",
  "question": "What is the mechanism of action of peginesatide?",
  "ideal_answer": "Peginesatide (Omontys) is synthetic, PEGylated, peptide-based erythropoiesis-stimulating agent that is designed to specifically stimulate the erythropoietin receptor. It was recalled because of serious side-effects including cases of death.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/22406924",
    "http://www.ncbi.nlm.nih.gov/pubmed/24748667",
    "http://www.ncbi.nlm.nih.gov/pubmed/24905967",
    "http://www.ncbi.nlm.nih.gov/pubmed/23840463",
    "http://www.ncbi.nlm.nih.gov/pubmed/27551882",
    "http://www.ncbi.nlm.nih.gov/pubmed/22935486",
    "http://www.ncbi.nlm.nih.gov/pubmed/23675762",
    "http://www.ncbi.nlm.nih.gov/pubmed/23318685",
    "http://www.ncbi.nlm.nih.gov/pubmed/20730698",
    "http://www.ncbi.nlm.nih.gov/pubmed/21290916",
    "http://www.ncbi.nlm.nih.gov/pubmed/23111861",
    "http://www.ncbi.nlm.nih.gov/pubmed/23343062",
    "http://www.ncbi.nlm.nih.gov/pubmed/24348017",
    "http://www.ncbi.nlm.nih.gov/pubmed/26079829",
    "http://www.ncbi.nlm.nih.gov/pubmed/23343061",
    "http://www.ncbi.nlm.nih.gov/pubmed/22188389",
    "http://www.ncbi.nlm.nih.gov/pubmed/23847411",
    "http://www.ncbi.nlm.nih.gov/pubmed/22719216",
    "http://www.ncbi.nlm.nih.gov/pubmed/22192713",
    "http://www.ncbi.nlm.nih.gov/pubmed/21710591",
    "http://www.ncbi.nlm.nih.gov/pubmed/21816551",
    "http://www.ncbi.nlm.nih.gov/pubmed/23989045",
    "http://www.ncbi.nlm.nih.gov/pubmed/24023516",
    "http://www.ncbi.nlm.nih.gov/pubmed/22884786",
    "http://www.ncbi.nlm.nih.gov/pubmed/24584613",
    "http://www.ncbi.nlm.nih.gov/pubmed/27279382",
    "http://www.ncbi.nlm.nih.gov/pubmed/22592927",
    "http://www.ncbi.nlm.nih.gov/pubmed/26122516",
    "http://www.ncbi.nlm.nih.gov/pubmed/23506424",
    "http://www.ncbi.nlm.nih.gov/pubmed/23338536",
    "http://www.ncbi.nlm.nih.gov/pubmed/21649477",
    "http://www.ncbi.nlm.nih.gov/pubmed/23243269",
    "http://www.ncbi.nlm.nih.gov/pubmed/22642238",
    "http://www.ncbi.nlm.nih.gov/pubmed/22971699",
    "http://www.ncbi.nlm.nih.gov/pubmed/27174804",
    "http://www.ncbi.nlm.nih.gov/pubmed/21940838",
    "http://www.ncbi.nlm.nih.gov/pubmed/22745925"
  ],
  "snippets": [
    {
      "text": "The erythropoietin-mimetic peptide (EMP) peginesatide belongs to the group of erythropoiesis-stimulating agents (ESAs) that are prohibited when misused in sports. Peginesatide is a synthetic pegylated homodimer of two cyclic 21-amino acid chains. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27279382",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Epo mimetic peptides have also raised expectations. Yet the prototype peginesatide was recalled after just 1 year of its widespread use in the USA because of serious side-effects including cases of death.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24748667",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The erythropoietin analog peginesatide was withdrawn from marketing due to unexpected severe anaphylactic reactions associated with administration of the multi-use formulation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26079829",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Method characterization was conducted for the EMP-based drug peginesatide concerning specificity, linearity, precision, recovery, stability, ion suppression/enhancement, and limit of detection (LOD, 0.25 ng/mL).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26122516",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Peginesatide, a long-acting erythropoiesis-stimulating agent, was recalled in February 2013 following reports of serious and sometimes fatal hypersensitivity reactions in dialysis patients who received a first dose. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24905967",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND OBJECTIVES: Peginesatide (Omontys) is a novel, synthetic, PEGylated, peptide-based erythropoiesis-stimulating agent (ESA) that is designed to specifically stimulate the erythropoietin receptor. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23243269",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Peginesatide, a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the erythropoietin receptor dimer that governs erythropoiesis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23318685",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Peginesatide, a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the erythropoietin receptor dimer that governs erythropoiesis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23318685",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Peginesatide is a synthetic, PEGylated, investigational, peptide-based erythropoiesis-stimulating agent that is designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21816551",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Peginesatide is a peptide-based erythropoiesis-stimulating agent that was designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22935486",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Peginesatide is a synthetic, PEGylated, peptide-based erythropoiesis-stimulating agent that is designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22406924",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Peginesatide is a peptide-based erythropoiesis-stimulating agent (ESA) that may have therapeutic potential for anemia in patients with advanced chronic kidney disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23343062",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The pharmacokinetics (PK) (absorption, distribution, metabolism, excretion) of peginesatide, a synthetic, PEGylated, investigational, peptide-based erythropoiesis-stimulating agent (ESA), was evaluated in rats.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22188389",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in rats.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22188389",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Peginesatide is an investigational pegylated, peptide-based, once-monthly ESA for increasing and maintaining hemoglobin (Hb).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21290916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21290916",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Peginesatide is a synthetic, PEGylated, investigational, peptide-based erythropoiesis-stimulating agent that is designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis. It is undetectable using current anti-doping tests due to its lack of sequence homology to EPO.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21816551",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Peginesatide, a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the erythropoietin receptor dimer that governs erythropoiesis. Studies were designed to determine the erythropoietic response, pharmacokinetics (PK), tissue distribution, metabolism, and excretion of peginesatide in nonhuman primates following a single i.v.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23318685",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Peginesatide, a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the erythropoietin receptor dimer that governs erythropoiesis. Studies were designed to determine the erythropoietic response, pharmacokinetics (PK), tissue distribution, metabolism, and excretion of peginesatide in nonhuman primates following a single i.v. dose.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23318685",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Peginesatide is a synthetic, PEGylated, investigational, peptide-based erythropoiesis-stimulating agent that is designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis. It is undetectable using current anti-doping tests due to its lack of sequence homology to EPO. To detect and deter potential abuse of peginesatide, we initiated an industry/antidoping laboratory collaboration to develop and validate screening and confirmation assays so that they would be available before peginesatide reaches the market.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21816551",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Peginesatide is a synthetic, PEGylated, peptide-based erythropoiesis-stimulating agent that is designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis. Peginesatide has a unique structure that consists of a synthetic peptide dimer (with no sequence similarity to erythropoietin) conjugated to a 40-kDa PEG moiety. Peginesatide is being developed for the treatment of anemia associated with chronic kidney disease in dialysis patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22406924",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Peginesatide is a synthetic, PEGylated, peptide-based erythropoiesis-stimulating agent that is designed and engineered to stimulate specifically the erythropoietin receptor dimer that governs erythropoiesis. Peginesatide has a unique structure that consists of a synthetic peptide dimer (with no sequence similarity to erythropoietin) conjugated to a 40-kDa PEG moiety.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22406924",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21290916",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": []
}